Hyperfine Swoop vs ScreenPoint Transpara

Eight 510(k) records, the latest decided in August 2026, sit behind Transpara, which supports cancer detection on 2D and 3D mammograms and added a density tool under K232096. The vendor says the MASAI randomized trial in Swedish screening used it, and cites sensitivity of 80.5% against 73.8% for standard double reading at 98.5% specificity, from a Lancet paper by Lund University researchers. A breast screening service or an imaging center with FFDM or tomosynthesis units is the audience, and no price is public. Hyperfine's audience is a unit that wants brain MRI without building a shielded room, with the company reporting 48 Swoop units sold in FY2024 according to its 10-K summary. Mammographers have no use for Swoop, and a neuro ICU has no use for Transpara.